The French drugmaker, one of the world's largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday it plans to expand its U.S. manufacturing capacity through direct investments in Sanofi sites, and partnerships with other domestic manufacturers.
The U.S. made up about 47% of Sanofi's total revenue in the first quarter of 2025.
Several peers, including Roche (ROG.S) and Novartis (NOVN.S), have made similar announcements in recent weeks as they respond to Trump's push to onshore domestic manufacturing. U.S. counterparts such as Eli Lilly (LLY.N) and Johnson & Johnson (JNJ.N) have also done the same.
Analysts and industry executives have said any new manufacturing facility could take at least five years to begin production. But last week, Trump signed an executive order that aims to reduce the time it takes to approve pharmaceutical plants in the country.
Sanofi said money would also go towards a substantial increase in spending on research and development in the country, and is expected to create "a significant number of high-paying jobs in multiple states in the coming years".
Since taking office, Trump has repeatedly threatened to levy tariffs on medicines. His administration is conducting an investigation into imports of pharmaceuticals in an effort to impose tariffs on national security grounds.
Rates and timing remain uncertain, but the industry has been lobbying for phased-in tariffs.
